NCT05838950Recruiting
HIIT Effects on Cardiometabolic Health
Detraining Effect of Short-term HIIT on Cardiometabolic Risk in Young Adults With Obesity
Source: ClinicalTrials.gov · Last updated 23 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-clinical markers of cardiovascular disease, blood lipids and fasting glucose will be measured at the following three time points: baseline, post-intervention, and 2 weeks after the training cessation (i.e., measure for detraining effect). All measurements will be performed three days before the training program and three days after the intervention to avoid the effect of the last training session. Afterwards, the detraining test will be measured 2 weeks post intervention.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 13 Feb 2023
- Start date
- 29 Sept 2023
- Primary completion date
- 23 Aug 2025
- Lead sponsor
- Syracuse University
- Diseases
- Obesity
- NCT number
- NCT05838950
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 29 Sept 2023 to the primary completion date, 23 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking weight loss medication(s)
- Currently enrolled (or within previous 6 months) in a weight loss program;
Other illness
- Syndromic obesity; 1) Any clinical symptoms including cognitive delay, 2) abnormalities in body structure(s), 3) organ-specific abnormalities (kidney, liver failure, excessive eating, and/or other signs of hypothalamic dysfunction such as fatigue, weakness and/or lack of interest in activities.
- An underlying disease/medications (steroids, second generation psychotropic agents, hormonal contraception, statins, antihypertensive and antidiabetic medications) that could influence carbohydrate or lipid metabolism.
- Presence of cardiac pacemaker.
Other
- Current or anticipated participation in another research that would interfere with any of the outcomes.
- Current or anticipated pregnancy.
Who the study is looking for
- Young adults with obesity (Age 18 to 25 years old, BMI ≥ 30 kg/m2).
Age in the registry: 18 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Women's Building Coordinator of this site? Confirm its status | Syracuse | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.